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Original Article
Value of neutrophil to lymphocyte ratio as a predictor of mortality 
in patients undergoing aortic valve replacement
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Background: Neutrophil to lymphocyte ratio (NLR) has been studied as a measure of inflammation and as 
a prognosticating factor in various medical conditions including neoplastic, inflammatory and cardiovascular. 
The prognostic role of NLR in predicting mortality in patients with aortic stenosis undergoing surgical 
aortic valve replacement (AVR) has not been studied. The aim of our study is to explore the utility of NLR as 
a predictor of both, short and long-term mortality, in patients undergoing surgical AVR.
Methods: Consecutive patients with aortic stenosis admitted for AVR to our institution were evaluated for 
study inclusion. Of the 335 patients admitted from January 2007 to September 2011, 234 met study inclusion 
criteria. Patients were divided into two groups depending on their initial preoperative NLR level with a 
cutoff value of 3. Three-year vital status was accessed with electronic medical records and Social Security 
Death Index. Survival analysis, stratified by NLR, was used to evaluate the predictive value of preoperative 
NLR levels.
Results: Patients with NLR ≥3, when compared to those with NLR <3, had a significantly higher short-
term (9.40% vs. 0, P=0.0006), 6-month (19.54% vs. 0.95%, P<0.0001), and 3-year mortality (27.35% 
vs. 3.78%, P<0.0001). After adjustment for baseline characteristics, co-morbidities, symptomatology, 
echocardiographic findings, and blood tests, NLR level remained a significant independent predictor of 3-year 
mortality; Hazard ratios (HRs) increased by a factor of 1.18 (1.05–1.33, P=0.0068) and patients with a NLR 
≥3 had 4.77 fold increase in 3-year mortality (1.48–15.32, P=0.0090).
Conclusions: NLR is an independent predictor of short-term and long-term mortality in patients with 
aortic stenosis undergoing AVR surgery, especially those with NLR ≥3. We strongly suggest the use of NLR 
as a tool to risk stratify patients with aortic stenosis undergoing AVR surgery.
Keywords: Neutrophil to lymphocyte ratio (NLR); aortic valve stenosis; surgical aortic valve replacement (surgical 
AVR); mortality
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Introduction
Calcific aortic valve stenosis is the most common valvular 
heart disease in the western world (1). Surgical aortic 
valve replacement (AVR) represents the gold standard of 
treatment, when indicated, with around 67,500 procedures 
done annually in the United States (2). 
Calcific aortic valve disease is an indolent disease with 
a spectrum that ranges from mild valve thickening, aortic 
sclerosis, to severe calcification and impaired leaflet motion, 
aortic stenosis. This process was thought to be degenerative 
and a consequence of time-dependent leaflet damage and 
calcium deposition (3). Clinical aortic stenosis doesn’t 
uniformly affect the elderly, with an estimated prevalence 
of only 3% to 5% in patients aged 75 or more (4,5). 
This suggests that other factors, besides age-related 
degeneration, play a major role in the disease pathogenesis. 
Evidence of chronic inflammation has been found, by 
immunohistochemical studies, in aortic valve leaflets; with 
the presence of macrophages and T lymphocytes, which 
release inflammatory cytokines. These inflammatory cells 
and cytokines help stimulate fibrotic and calcific processes, 
which in turn increase valve stiffness (3). Presence 
of chronic inflammation is also supported by studies 
demonstrating increased systemic C-reactive protein in 
patients with aortic stenosis (6), increased temperature in 
stenotic aortic valve cusps (7), and increased 18F-sodium 
fluoride (18F-NaF) uptake with the use of positron emission 
tomography, with progressive rise in activity with increasing 
valve severity (8).
Several studies showed that elevated neutrophil to 
lymphocyte ratio (NLR) is a significant predictor of adverse 
outcomes for patients with cardiovascular disease including 
stable coronary artery disease, acute coronary syndrome, 
heart failure and aortic stenosis. Additionally, a relationship 
between NLR and the severity of calcific aortic stenosis has 
been found (9-13).
Our objective in this study is to examine the utility of 
NLR as a predictor of short- and long-term mortality in 
patients with calcific aortic stenosis undergoing surgical 
AVR.
Methods
This longitudinal retrospective observational study 
examined the usefulness of NLR value as a predictor of 
survival in 335 patients who underwent AVR between 
January 2007 and September 2011. Patients undergoing 
non-emergent, AVR, secondary to aortic valve stenosis, 
were evaluated for study inclusion. Study exclusion 
criteria included age >85 years, clinical evidence of 
infective endocarditis or any other active infection, cancer, 
hematopoietic disease, autoimmune or inflammatory 
diseases, current steroid or chemotherapy use, emergent 
valve replacement, acute coronary syndrome on admission, 
and incomplete medical records. Two hundred and thirty-
four patients out of the 335 were eligible for the study 
inclusion (Figure 1). All-cause short-term (30 days), 
6-month, and 3-year mortality were obtained from 
electronic medical records and Social Security Death Index. 
This study was approved by the institutional review board 
of Saint Joseph Regional Medical Center.
White blood cell (WBC) counts and differentials were 
obtained from the first, pre-operative blood tests on index 
admissions. Differential leukocyte counts were obtained 
using automated blood cell counter. Electronic medical 
records were reviewed, independently, by two physicians for 
baseline characteristics, presenting symptoms, preoperative, 
in-hospital laboratory values, preoperative echocardiographic 
findings, and AVR surgical reports (Table 1). Aortic 
valve area, mean aortic flow gradient, presence of aortic 
insufficiency and other valvular pathologies were obtained 
from preoperative transthoracic and/or transesophageal 
echocardiograms. Smoking history included any current or 
previous smoking. 
The patients were dichotomized based on their NLR, 
NLR ≥3 and <3. The cutoff value for NLR was calculated 
by testing all possible cutoffs that would discriminate 
between mortality by Cox proportional analyses. The cutoff 
value was then rounded to a clinically convenient value. 
Variables were assessed for the normality of distribution 
using D’Agostino-Pearson test. Continuous variables 
were presented as means ± SDs and categorical variables 
were presented as frequencies and percentages. Group 
comparisons used chi-square analysis for categorical 
variables. Continuous variables were compared using 
analysis of variance or Mann-Whitney U-test, depending on 
the probability distribution of the variable. All probabilities 
were 2-sided and P values <0.05 were considered statistically 
significant. 
Univariate Cox proportional hazard models were used to 
examine the association of NLR and all other variables with 
long-term mortality. Then, a multivariate Cox proportional 
hazard model, adjusted for all predictors of long-term 
mortality of the univariate analysis and significant 
baseline characteristics was done. We confirmed that the 
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proportionality of hazards assumption was met. Kaplan-
Meier curves were used to illustrate the difference in 3-year 
survival function between the two groups. 
Leukocytes and platelets parameters were investigated 
for superiority of mortality prediction in two ways. First, 
each leukocyte parameter was compared between survivor 
and mortality groups using Kruskal-Wallis test or analysis 
of variance, depending on normality of data distribution. 
Second, multivariate Cox proportional hazard model using 
leukocyte and platelets parameters was done.
All data were analyzed using MedCalc version 15.2.2 
(MedCalc Software bvba, Belgium) and SPSS 22 (IBM 
Corp., USA).
Results
The primary outcome was all-cause 3-year mortality. 
Thirty-nine deaths occurred in the 234 patients (16.7%). 
Figure 2 illustrates significant higher short-term (9.40% vs. 
0, P=0.0006), 6-month (19.54% vs. 0.95%, P<0.0001), and 
3-year mortality (27.35% vs. 3.78%, P<0.0001) in patients 
with NLR ≥3, when compared to those with NLR <3. 
Three-year Kaplan-Meier curves shows that patients with 
NLR ≥3 had significantly worse short, 6-month, and 3-year 
mortalities than patients with NLR <3 (Mantel-Cox Chi-
square 10.4, 20.17, 23.40 respectively, P<0.001; Figure 3). 
In the high NLR group, there was a significantly 
higher prevalence of symptoms of heart failure (44.34% 
vs. 59.38%, P=0.03), lower ejection fraction (51.08±10.28 
vs. 45.47±12.13, P=0.0001), preoperative presence of atrial 
fibrillation (16.04% vs. 28.13%, P=0.03), and higher serum 
creatinine levels (1.12±1.18 vs. 1.38±1.38, P=0.0012) when 
compared to those with lower NLR. However, angina was 
significantly higher in the lower NLR group (53.77% vs. 
39.84%, P=0.04). 
Leukocyte parameters, including neutrophils and 
lymphocytes, total WBC, and NLR significantly differed 
by patients’ vital status (P=0.02452, P=0.00015, P=0.03460, 
P<0.0001, respectively; Table 2). Of all, NLR was the best 
predictor of mortality (Kruskal-Wallis Chi-square 22.03, 
P<0.0001). Leukocyte parameters, WBC, and NLR adjusted 
mortality hazards also indicated that NLR significantly 
predict long term mortality [hazard ratio (HR) =1.27, 95% 
CI, 1.17–1.39], whereas the rest failed to demonstrate a 
significant mortality hazard. 
In the univariate Cox regression analysis, patients with an 
NLR ≥3 had an 8.39 fold increase risk of 3-year mortality 
(HR =8.39; 95% CI, 3.00–23.48, P=0.0001). Univariate 
analysis also identified end-stage renal disease, hypertension, 
history of cerebrovascular accident, preoperative ejection 
Figure 1 Schematic illustration of study design and patients’ vital status.
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Table 1 Variables of patients undergoing AVR according to neutrophil/lymphocyte ratio dichotomization
Baseline characteristics NLR <3 (n=106) NLR ≥3 (n=128) P value
Age (years) 69.43±12.04 71.59±10.71 0.17
Male gender 61 (57.55%) 75 (58.59%) 0.89
Hypertension 88 (83.02%) 98 (76.56%) 0.26
Diabetes millets 36 (33.96%) 48 (37.50%) 0.59
Hyperlipidemia 73 (68.87%) 74 (57.81%) 0.10
End-stage renal disease 2 (1.89%) 10 (7.81%) 0.07
History of myocardial infarction 11 (10.38%) 11 (8.59%) 0.66
History of smoking 20 (18.87%) 27 (21.09%) 0.74
History of cerebrovascular event 10 (9.43%) 7 (5.47%) 0.31
Previous coronary artery bypass surgery 8 (7.55%) 15 (11.72%) 0.38
Previous coronary angioplasty 14 (13.21%) 21 (16.41%) 0.58
Previous valve surgery 3 (2.83%) 2 (1.56%) 0.66
Presentation
Syncope 8 (7.55%) 8 (6.25%) 0.80
Angina 57 (53.77%) 51 (39.84%) 0.04
Symptoms of heart failure 47 (44.34%) 76 (59.38%) 0.03
Preoperative atrial fibrillation 17 (16.04%) 36 (28.13%) 0.03
Preoperative aortic valve area (cm2) 0.77±0.22 0.72±0.18 0.11
Preoperative aortic valve mean gradient (mmHg) 49.05±14.35 50.6±20.53 0.92
Preoperative aortic insufficiency 52 (49.06%) 51 (39.84%) 0.19
Preoperative ejection fraction (%) 51.08±10.28 45.47±12.13 0.0001
Surgical variables
Concomitant CABG 45 (42.45%) 56 (43.75%) 0.69
Prosthetic valve size (mm) 22.19±2.03 22.19±2.05 0.89
Mean cardiopulmonary bypass time (minute) 57.9±6.62 57.6±5.05 0.64
Preoperative in-hospital laboratory data
Serum creatinine (mg/dL) 1.12±1.18 1.38±1.38 0.0012
Fasting blood sugar (mg/dL) 111.41±38.51 118.63±41.53 0.12
High-density lipoprotein (mg/dL) 40.94±16.56 37.34±12.86 0.35
Low-density lipoprotein (mg/dL) 102.72±42.19 94.95±51.83 0.13
First white blood cell count (×103 cells/µL) 6.83±1.6 7.95±2.07 <0.0001
First lymphocyte count (×103 cells/µL) 2.05±0.69 1.46±1.70 <0.0001
First neutrophil count (×103 cells/µL) 4±1.12 6.23±5.48 <0.0001
First platelet count (×103 cells/µL) 213.86±62.60 215.70±87.83 0.49
Neutrophil/lymphocyte ratio 2.07±0.58 4.76±2.28 <0.0001
AVR, aortic valve replacement; NLR, neutrophil to lymphocyte ratio; CABG, coronary artery bypass graft.
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Figure 2 Thirty-day, 6-month, and 3-year all-cause mortality rates in patients between different NLR groups. NLR, neutrophil to 
lymphocyte ratio.
Figure 3 Kaplan-Meier curve showing 3-year all-cause mortality according to NLR dichotomization; NLR <3 (solid line) and NLR ≥3 
(dashed line). NLR, neutrophil to lymphocyte ratio.
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Table 2 Comparison of different leukocyte parameters, total WBC, and platelets in survivors and mortality groups
Leukocyte parameter
Median according to vital status Kruskal-Wallis/ANOVA
1-month mortality 6-month mortality 3-year mortality Alive Chi-square or F P value
NLR 4.23 3.96 3.77 2.90 22.03 <0.0001
WBC 8.75 6.90 7.80 7.10 8.63 0.03460
Neutrophils 5.95 4.85 4.90 4.60 9.38 0.02452
Lymphocytes 1.35 1.10 1.40 1.70 20.17 0.00015
Platelet 214 169 195 206.5 3.25 0.35404
WBC, white blood cell; NLR, neutrophil to lymphocyte ratio; ANOVA, analysis of variance. 
Table 3 Univariate and multivariate Cox proportional hazards models of the association between clinical and laboratory parameters and 3-year 
mortality
Clinical and laboratory parameters Univariate HR (95% CI) P value Multivariate HR (95% CI) P value
NLR ≥3 8.39 (3.00–23.48) 0.0001 4.77 (1.48–15.32) 0.0090
NLR (continuous variable) 1.27 (1.17–1.39) <0.0001 1.18 (1.05–1.33) 0.0068
ESRD 6.60 (3.03–14.36) <0.0001 3.39 (1.06–10.89) 0.0413
History of CVA 3.32 (1.47–7.51) 0.0040 3.58 (1.42–9.07) 0.0074
Preoperative EF 0.95 (0.93–0.97) <0.0001 0.98 (0.95–1.00) 0.1310
Fasting blood sugar 1.01 (1.00–1.01) 0.0127 1.01 (1.00–1.01) 0.0586
Hypertension 5.22 (1.27–21.50) 0.0229 5.01 (1.08–23.26) 0.0409
Previous bypass surgery 2.49 (1.15–5.39) 0.0217 2.19 (0.89–5.39) 0.0901
Serum creatinine 1.24 (1.08–1.41) 0.0016 1.17 (0.92–1.48) 0.2142
Preoperative A-fib 1.06 (0.51–2.23) 0.8764 0.99 (0.45–2.16) 0.9776
Symptoms of HF 0.67 (0.35–1.27) 0.2180 0.72 (0.32–1.60) 0.4286
Symptoms of angina 0.64 (0.34–1.23) 0.1849 0.77 (0.38–1.55) 0.4723
NLR, neutrophil to lymphocyte ratio; CVA, cerebrovascular accident; EF, ejection fraction; HR, hazard ratio; HF, heart failure.
fraction, history of bypass surgery, and serum creatinine as 
prognosticators of mortality (Table 3). The rest of variables 
failed to show any statistical significance.
In a multivariate Cox regression analysis NLR was 
independently associated with a higher 3-year mortality 
with a HR increase by a factor of 1.3 (HR =1.3, 95% CI, 
1.18–1.44; P<0.0001) and a NLR ≥3 was associated with 
4.77-fold increase in 3-year mortality. The multivariate 
analysis was adjusted for the independent predictors of 
outcome: history of end stage renal disease, cerebrovascular 
event, hypertension, and bypass surgery; symptoms of heart 
failure, angina and A-fib; and ejection fraction, fasting 
blood sugar, and serum creatinine as continuous variables. 
Additionally, previous cerebrovascular accident and end-
stage renal disease were also found to be independent 
prognosticators of 3-year mortality (Table 3).
Discussion
The pathophysiology of calcific aortic valve disease 
is characterized by three primary processes:  l ipid 
accumulation, inflammation, and calcification (14). 
This disease process shares similar risk factors with 
atherosclerosis such as smoking, advanced age, male 
gender, metabolic syndrome, elevated lipoprotein (a) level, 
increased serum creatinine level, hypertension, diabetes 
mellitus, high low density lipoprotein-cholesterol and low 
level of high density lipoprotein-cholesterol (4,15-20). 
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The calcification of the aortic valve leaflets in AS are 
usually located on the aortic side of the leaflets, at the 
cusps coaptation lines and at the cusps attachment sites 
to the aortic wall and extend to the cusps. This pattern 
suggests that calcifications develop at sites of maximal 
mechanical stress. This was postulated to be the initiating 
factor in the disease process, in a similar manner to that 
of atherosclerosis, by causing endothelial injury (3). 
Histological studies have shown similarities between AS 
valvular lesions and atherosclerosis lesions. Inflammation 
manifests with T lymphocytes and macrophages which 
infiltrate the endothelium and release cytokines. These 
cytokines promote cellular proliferation and extracellular 
matrix remodeling by acting on valvular fibroblasts (3,21). 
Despite that, prospective randomized trials have failed 
to show a reduction in aortic valve calcific stenosis 
progression with anti-inflammatory, statin therapy (22,23). 
This might be a result of late initiation of statin therapy in 
the disease process, after reaching irreversible stages.
N L R  w a s  s t u d i e d  a s  a  p r o g n o s t i c  m a r k e r  i n 
atherosclerotic heart disease and cancer. Many authors 
reported that higher NLR values were associated with worse 
outcomes in patients with acute coronary syndrome, stable 
coronary artery disease, ST-segment elevation myocardial 
infarction, non-ST-segment elevation myocardial infarction 
and in patients undergoing percutaneous coronary 
interventions (12,24,25). Calcific aortic valve stenosis is a 
progressive disease, where the underlying pathophysiology 
of inflammation parallels that of atherosclerosis. Our study 
is the first study, to our knowledge, to examine the use 
of NLR value as a risk predictor for short and long-term 
mortality in patients diagnosed with severe AS undergoing 
AVR surgery.
NLR is a nonspecific marker of systemic inflammation. 
It represents a ratio between two different subtypes of 
leukocytes; neutrophils, which are part of the non-specific, 
innate immune system, and lymphocytes, which are part of 
the specific, regulatory pathway of the immune system. One 
major difficulty in using NLR value as a prognosticator in 
disease processes is determining an appropriate cut-off value 
around which disease outcomes differ. The appropriate NLR 
cut-off value is likely to change with the stage of illness, 
laboratory techniques employed, concomitant infection and 
patient demographic characteristics (26). In our study, a 
statistically significant difference in all-cause mortality was 
found between patients using the cutoff value of 3. 
Despite the normal range of the index white blood cell 
counts in both of our NLR groups, the high NLR group 
had statistically significant higher normal white blood cell 
count values. In addition, the high NLR group had lower 
lymphocyte counts, as well as higher neutrophil counts, 
leading to the statistically significant higher NLR values. 
It is clear that NLR carries more information than its 
constituent elements especially when the absolute counts of 
these elements are in the normal range. 
In our study, there was a higher prevalence of certain 
co-morbid conditions in the high NLR group (NLR 
≥3). Those co-morbid conditions are symptomatic heart 
failure, lower ejection fraction (EF), preoperative atrial 
fibrillation, and elevated serum creatinine level. This is 
consistent with prior studies that showed an elevated NLR 
in these conditions (27-30). There was a higher prevalence 
of end-stage renal disease (ESRD) in the high NLR 
group; however, this was not statistically significant in our 
sample. The prevalence of angina was higher in the low 
NLR group; this is consistent with the fact that angina is 
associated with the longest median survival (approximately 
5 years) in patients with severe AS when compared to heart 
failure and syncope (31). 
Prior studies have demonstrated that risk factors such as 
tobacco use, diabetes mellitus, dyslipidemia, hypertension 
and coronary artery disease, have significant correlations 
(positive or negative) with NLR (32-35), however, both 
NLR groups in our study did not statistically differ in the 
prevalence of these conditions.
In our study, pre-operative NLR was demonstrated to 
predict short- and long-term mortality after AVR surgery 
in patients diagnosed with severe AS. It is not clear whether 
high NLR is related to the pathogenic process of AS or 
it is a component or marker of one or many unrelated 
deleterious systemic pathologic conditions that continue 
unabated after AVR increasing mortality rates in the high 
NLR group. It is also unclear whether high NLR has an 
etiological role in the increased mortality rates or it is just a 
marker of the etiological condition(s) of increased mortality. 
Assuming that high NLR is related to the pathogenesis of 
AS, the fact that higher mortality rates continue to occur 
after having a new prosthetic aortic valve in place, in the 
high NLR group, suggests that the disease process of AS 
is systemic and not confined to the aortic valve. Another 
possibility is that high NLR is a component or marker of a 
systemic abnormality that has many manifestations, with AS 
being one manifestation, but other manifestations continue 
to evolve over time after AVR leading to increased mortality.
The main limitation of our study is the non-randomized, 
retrospective, single-center, observational design. Our 
171Cardiovascular Diagnosis and Therapy, Vol 8, No 2 April 2018
© Cardiovascular Diagnosis and Therapy. All rights reserved. Cardiovasc Diagn Ther 2018;8(2):164-172cdt.amegroups.com
study included a small number of patients which may have 
led to selection bias. A large multicenter prospective study 
that uses a clinically relevant NLR cut-off value is needed 
to establish NLR as a true prognostic factor in patients 
diagnosed with severe AS undergoing AVR surgery.
Conclusions 
NLR is an independent predictor of short- and long-term 
mortality in patients with aortic stenosis undergoing AVR 
surgery. Patients with a NLR ≥3 had a statically significant 
mortality. We strongly suggest the use of NLR as a tool to 
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